Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Galera Labs LLC is active in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is assigned to a distinct examiner and is being reviewed within 1 distinct art unit. This represents a narrow and focused prosecution effort for the company's pharmaceutical intellectual property. This concentration allows for a streamlined approach to patent strategy, as the applicant only needs to navigate the specific requirements of the involved administrative unit.
The busiest examiner for this portfolio is CUTLIFF, YATE KAI RENE, who is responsible for 1 busiest examiner pending office action. Since the total number of pending actions is limited, this examiner is the only one currently reviewing the company's applications. Practitioners can focus their efforts on the specific examination style of this examiner and the standards of the 1 distinct art unit involved. The lack of diversity in examiners and units means that the outcome of this specific action will significantly impact the company's current patent standing in the biotechnology field. Understanding the specific examination history and preferences of this official is crucial for successfully advancing the company's interests.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUTLIFF, YATE KAI RENE | 1 | 79.8% | +24.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598300 | METHOD OF MANUFACTURE OF PENTAAZA MACROCYCLIC RING COMPLEX, INTERMEDIATES, AND PRODUCTS THEREOF | CUTLIFF, YATE KAI RENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598300 | METHOD OF MANUFACTURE OF PENTAAZA MACROCYCLIC RING COMPLEX, INTERMEDIATES, AND PRODUCTS THEREOF | CUTLIFF, YATE KAI RENE | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598300 | METHOD OF MANUFACTURE OF PENTAAZA MACROCYCLIC RING COMPLEX, INTERMEDIATES, AND PRODUCTS THEREOF | CUTLIFF, YATE KAI RENE | 1692 | §102§103 | Non-Final OA | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGalera Labs LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yate Kai Rene Cutliff has the most, with 1 of Galera Labs LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
